Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
2'-F-RNA
Human Osteopontin
Protein
18 nM (reported value)
Binding Buffer: PBS (137 nM NaCl, 27 nM KCl, 100 nM Na2HPO4, 2 nM K2HPO4, pH 7.4)
37°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
OPN-R3 prevents the binding of osteopontin to CD44 and av??3. It was found to inhibit MDA-MB231 adhesion, migration, and invasion in Matrigel-based assays.
Osteopontin (OPN-R3) (ID# 370)
5'fCprGprGpfCpfCprApfCprAprGprAp rApfUprGprAprAprAprAprApfCpfCp fUpfCprApfUpfCprGprApfUprGpfUp fUprGpfCprApfUprAprGpfUpfUprGp 3'
41
12862.72 g/mole
402900 L/(mole·cm)
45.00%
2.48
31.93
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Z Mi et al. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Molecular Therapy 17(2009): 153-161
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.